đŸ› ïž We are currently updating the documentation of our products. Thank you for your understanding.

📅 Published in Monday, October 13 of 2025

Innovation meets reality: navigating the challenges of next-generation therapies
Cell and gene therapies are transforming modern medicine—offering curative potential for diseases once considered untreatable. Yet despite remarkable progress, the journey from discovery to large-scale treatment remains complex.

In the new Sartorius e-Book “Overcoming Barriers in Cell and Gene Therapy,” seven leading experts from across the industry share their perspectives on how to bridge the gap between research, clinical translation, and commercial success. Their insights shed light on the core challenges of reproducibility, scalability, and compliance—and how innovation can overcome them.


1. Tackling variability and cost barriers

High development costs and biological variability continue to limit accessibility. Experts highlight how standardizing upstream and downstream processes is key to reliable outcomes.

“Streamlining is crucial for entering clinical trials and proving efficacy,” notes Josh Sonico, Platform Development Specialist for Cells and Extracellular Vesicles at Sartorius.
With geometrically consistent bioreactor technologies, Sartorius aims to simplify scale-up and reduce risk at every stage of production.


2. Building reproducibility through precision

Reproducibility is the foundation of every therapy’s success. The e-Book explores how precise instrumentation, consistent materials, and data-driven process control enable scientists to generate reliable, validated results ready for regulatory approval.

These insights emphasize how advanced analytics and automation can close the gap between early R&D variability and commercial-grade reproducibility.


3. From lab to market: achieving true scalability

Transitioning from small-scale development to full manufacturing remains one of the greatest bottlenecks in the field.
Through aseptic harvesting techniques and digital twin technologies, manufacturers can accelerate process transfer and streamline decision-making—ensuring that promising therapies reach patients faster and more efficiently.

“The primary questions now revolve around reducing costs and making these therapies more accessible,” says Randall Alfano, Segment Technology Manager for Cell Therapy at Sartorius.


4. Ensuring compliance through technology

Compliance doesn’t just protect patients—it sustains innovation. The experts detail how integrated digital solutions can guarantee data integrity, validation, and traceability throughout therapy development.
From audit-ready documentation to smart process tracking, these solutions reduce regulatory friction and improve confidence in product quality.


Explore the complete expert e-Book

The Sartorius e-Book offers a consolidated view of strategies shaping the future of advanced therapies. Inside, you’ll find interviews, case insights, and forward-looking solutions for every stage of development—from discovery to commercial production.

đŸ“„ Read the full e-Book


Redefining what’s possible in advanced therapies

From bioreactors engineered for seamless scale-up to data systems ensuring transparency and trust, Sartorius continues to drive the next chapter in cell and gene therapy innovation.
Together, the industry is moving toward a future where precision, accessibility, and compliance coexist—turning today’s experimental promise into tomorrow’s reality.

Scroll to Top